{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:05:32Z","timestamp":1765976732499,"version":"3.40.5"},"reference-count":28,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Before immunotherapy became part of the management of metastatic bladder cancer (mBC), systemic anti-cancer treatment comprised primarily of platinum-based chemotherapy. The objective of this study was to describe the characteristics, the initial management, overall survival (OS) and hospitalisations of patients with mBC before 2018 when immunotherapy for mBC was introduced in Norway.\u00a0\nMaterial and methods: It is a nationwide population-based study of primary mBC patients (diagnosed 2008-16). Descriptive statistics were applied and stratified for four initial management options (\u2264150 days after BC diagnosis): chemotherapy, major local treatment (cystectomy\/pelvic radiotherapy), multimodal treatment (chemotherapy and local) and no anti-cancer treatment beyond transurethral resection of bladder tumour (untreated). Group differences were evaluated by Chi-square and Kruskal\u2013Wallis test; OS was estimated with Kaplan\u2013Meier.\nResults: Of the 305 patients included, 76 (25%) patients had chemotherapy, 46 (15%) patients had major local treatment, 21 (7%) patients had multimodal treatment and 162 (53%) patients were untreated.\u00a0 Median OS ranged from 2.3 months (untreated) to 9.8 months (chemotherapy). Patients who received treatment had a higher rate of hospitalisation, with a median stay of three to four times that of untreated patients.\nConclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.<\/jats:p>","DOI":"10.2340\/sju.v58.5923","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T12:21:44Z","timestamp":1699618904000},"page":"101-108","source":"Crossref","is-referenced-by-count":2,"title":["Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway"],"prefix":"10.2340","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1916-4094","authenticated-orcid":false,"given":"Christina Tanem","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-5048","authenticated-orcid":false,"given":"Gunnar","family":"Tafjord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-2841","authenticated-orcid":false,"given":"Augun","family":"Blindheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-5794","authenticated-orcid":false,"given":"Viktor","family":"Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-2217","authenticated-orcid":false,"given":"Sophie","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5087-2913","authenticated-orcid":false,"given":"Bettina Kulle","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"40940","doi-asserted-by":"crossref","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"40941","unstructured":"Witjes JA, Cathomas R, Comp\u00e9rat E, et al. The EAU Guidelines on Muscle-invasive and Metastatic bladder cancer 2022. [Accessed Aug, 2022] Available from: https:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/"},{"key":"40942","doi-asserted-by":"crossref","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"40943","doi-asserted-by":"crossref","unstructured":"Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15(7):2564\u20139. https:\/\/doi.org\/10.1200\/JCO.1997.15.7.2564","DOI":"10.1200\/JCO.1997.15.7.2564"},{"key":"40944","doi-asserted-by":"crossref","unstructured":"von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.07.757","DOI":"10.1200\/JCO.2005.07.757"},{"key":"40945","doi-asserted-by":"crossref","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u2018unfit\u2019 for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"40946","doi-asserted-by":"crossref","unstructured":"Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3): 506\u201313. https:\/\/doi.org\/10.1002\/cncr.22031","DOI":"10.1002\/cncr.22031"},{"key":"40947","doi-asserted-by":"crossref","unstructured":"De Santis M, Bellmunt J, Mead G, et al. Randomized phase II\/III trial assessing gemcitabine\/ carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u2018unfit\u2019 for cisplatin-based chemotherapy: phase II \u2013 results of EORTC study 30986. J Clin Oncol. 2009;27(33):5634\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.21.4924","DOI":"10.1200\/JCO.2008.21.4924"},{"key":"40948","doi-asserted-by":"crossref","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683","DOI":"10.1056\/NEJMoa1613683"},{"key":"40949","doi-asserted-by":"crossref","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"40950","doi-asserted-by":"crossref","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3): 312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"40951","doi-asserted-by":"crossref","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788","DOI":"10.1056\/NEJMoa2002788"},{"key":"40952","doi-asserted-by":"crossref","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600. https:\/\/doi.org\/10.1200\/JCO.19.01140","DOI":"10.1200\/JCO.19.01140"},{"key":"40953","doi-asserted-by":"crossref","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807","DOI":"10.1056\/NEJMoa2035807"},{"key":"40954","unstructured":"Cancer in Norway 2021 \u2013 cancer incidence, mortality, survival and prevalence in Norway [Internet]. Oslo: Cancer Registry of Norway; 2022. [Cited Aug, 2022] Available from: https:\/\/www.kreftregisteret.no\/globalassets\/cancer-in-norway\/2021\/cin_report.pdf [cited 2022]."},{"key":"40955","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lgning av bl\u00e6rekreft Oslo: Helsedirektoratet; 2013. Available from: https:\/\/blaerekreft.no\/wp-content\/uploads\/Nasjonalt-handlingsprogram-bl%C3%A6rekreft.pdf [cited 3 August 2021]."},{"key":"40956","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av bl\u00e6re- og urotelkreft 2021. [Cited Aug, 2022] Available from: https:\/\/www.helsedirektoratet.no\/produkter?tema=retningslinje"},{"key":"40957","doi-asserted-by":"crossref","unstructured":"Flannery K, Cao X, He J, et al. Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy. Clin Genitourin Cancer. 2018;16(4):e909\u201317. https:\/\/doi.org\/10.1016\/j.clgc.2018.03.002","DOI":"10.1016\/j.clgc.2018.03.002"},{"key":"40958","doi-asserted-by":"crossref","unstructured":"Richters A, Mehra N, Meijer RP, et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25:100266. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100266","DOI":"10.1016\/j.ctarc.2020.100266"},{"key":"40959","doi-asserted-by":"crossref","unstructured":"Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the united states. Bladder Cancer. 2018;4(2):227\u201338. https:\/\/doi.org\/10.3233\/BLC-170149","DOI":"10.3233\/BLC-170149"},{"key":"40960","doi-asserted-by":"crossref","unstructured":"Larsen IK, Sm\u00e5stuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.037","DOI":"10.1016\/j.ejca.2008.10.037"},{"key":"40961","doi-asserted-by":"crossref","unstructured":"Bakken IJ, Ariansen AMS, Knudsen GP, et al. The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries. Scand J Public Health. 2019;48(1):49\u201355. https:\/\/doi.org\/10.1177\/1403494819859737","DOI":"10.1177\/1403494819859737"},{"key":"40962","unstructured":"Nasjonal tjeneste for validering og dekningsgradsanalyser \u2013 \u00c5rsrapporter: Helsedirektoratet. [Cited Sep, 2022] Available from: https:\/\/www.helsedirektoratet.no\/rapporter\/nasjonal-tjeneste-for-validering-og-dekningsgradsanalyser-og-arsrapport."},{"key":"40963","doi-asserted-by":"crossref","unstructured":"Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107\u201313. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979","DOI":"10.1200\/JCO.2011.38.6979"},{"key":"40964","doi-asserted-by":"crossref","unstructured":"Veskim\u00e4e E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncolgy. 2019;2(6):625\u201342. https:\/\/doi.org\/10.1016\/j.euo.2019.09.003","DOI":"10.1016\/j.euo.2019.09.003"},{"key":"40965","doi-asserted-by":"crossref","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173\u201381. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3173","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"40966","doi-asserted-by":"crossref","unstructured":"Reesink DJ, van de Garde EMW, Peters BJM, et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. 2020;10(1):15822. https:\/\/doi.org\/10.1038\/s41598-020-72820-y","DOI":"10.1038\/s41598-020-72820-y"},{"key":"40967","doi-asserted-by":"crossref","unstructured":"Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2021;24:1\u20138. https:\/\/doi.org\/10.1016\/j.euros.2020.12.002","DOI":"10.1016\/j.euros.2020.12.002"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/5923\/30477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/5923\/30477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T12:21:56Z","timestamp":1699618916000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/5923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/sju.v58.5923","relation":{},"ISSN":["2168-1813","2168-1805"],"issn-type":[{"type":"electronic","value":"2168-1813"},{"type":"print","value":"2168-1805"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}